Table 5. Treatment options and outcome in relation to tumour stage for all patients.
n | TRT option | St I | St II | St III | St IV | St X | Recurrence (recurr)/progression (progr) | n death/cause |
Definitive IMRT (48 patients) | ||||||||
18 | RT | 4 | 9 | 4** | 0 | 1 | 2 Tu recurr, 1 LN recurr | 1 postop complic, 1 LN recurr, 2nd primary |
10 | CRT | 0 | 3* | 2** | 5 | 0 | 1 Tu recurr, 1 Tu & LN recurr, 1 Tu progr | 1 Tu progr, 2 × 2nd primary, 1 toxic death |
2 | ICT→RT | 1 | 0 | 0 | 1 | 0 | ||
18 | ICT→CRT | 0 | 1 | 1 | 16 | 0 | 1 Tu recurr, 2 LN recurr, 1 Tu & LN recurr, | 1 Tu recurr, 1 LN recurr & liver M+, |
4 Tu progr, 1 LN progr | 3 Tu progr, 1 Tu progr & skin/lung M+ | |||||||
Post-operative IMRT (30 patients) | ||||||||
23 | RT | 2 | 6 | 8 | 7 | 0 | 1 Tu & LN recurr, 1 Tu progr | 1 Tu progr & lung M+, 1 intercurrent death |
7 | CRT | 0 | 1 | 1 | 5 | 0 | 1 Tu recurr | 1 Tu recurr |
TRT, treatment; postop, post-operative; CRT, concurrent chemotherapy and IMRT; ICT, induction chemotherapy; RT, radiotherapy; IMRT, intensity modulated radiotherapy; St, stage; M+, metastasis; Tu, primary tumour; LN, lymph node; complic, complication.
*Salvage surgery in 1 patient; **salvage surgery in 2 patient.